{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:36:17Z","timestamp":1766547377748,"version":"3.48.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-025-01468-5","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:33:28Z","timestamp":1766547208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secondary and Tertiary Hyperparathyroidism among Patients with X-Linked Hypophosphatemia: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5343-0813","authenticated-orcid":false,"given":"Samuel A.","family":"Fisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Zilberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Tudor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El Mahdi","family":"Benchekroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wally","family":"Landsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Rundle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred I.","family":"Neugut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"1468_CR1","doi-asserted-by":"publisher","first-page":"e10728","DOI":"10.1002\/jbm4.10728","volume":"7","author":"CF Munns","year":"2023","unstructured":"Munns CF, Maguire EP, Williams A et al (2023) Craniosynostosis in patients with X-Linked hypophosphatemia: a review. JBMR Plus 7:e10728. https:\/\/doi.org\/10.1002\/jbm4.10728","journal-title":"JBMR Plus"},{"key":"1468_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14:58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"1468_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15:435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"1468_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","volume":"127","author":"S DeLacey","year":"2019","unstructured":"DeLacey S, Liu Z, Broyles A et al (2019) Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127:386\u2013392. https:\/\/doi.org\/10.1016\/j.bone.2019.06.025","journal-title":"Bone"},{"key":"1468_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-025-01359-9","volume":"116","author":"N Ito","year":"2025","unstructured":"Ito N, Kang HG, Michigami T et al (2025) Prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in Asian patients with X-Linked Hypophosphatemic Rickets\/Osteomalacia. Calcif Tissue Int 116:50. https:\/\/doi.org\/10.1007\/s00223-025-01359-9","journal-title":"Calcif Tissue Int"},{"key":"1468_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Kooh SW, Sochett E (2003) Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol 58:163\u2013168. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01685.x","journal-title":"Clin Endocrinol"},{"key":"1468_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate","volume":"17","author":"A Gohil","year":"2019","unstructured":"Gohil A, Imel EA (2019) FGF23 and associated disorders of phosphate wasting. Pediatr Endocrinol Rev 17:17\u201334. https:\/\/doi.org\/10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate","journal-title":"Pediatr Endocrinol Rev"},{"key":"1468_CR8","doi-asserted-by":"publisher","first-page":"F739","DOI":"10.1152\/ajprenal.00321.2003","volume":"286","author":"AJ Brewer","year":"2004","unstructured":"Brewer AJ, Canaff L, Hendy GN, Tenenhouse HS (2004) Differential regulation of PHEX expression in bone and parathyroid gland by chronic renal insufficiency and 1,25-dihydroxyvitamin D3. Am J Physiol Renal Physiol 286:F739-748. https:\/\/doi.org\/10.1152\/ajprenal.00321.2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"1468_CR9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf357","author":"K Irie","year":"2025","unstructured":"Irie K, Kato H, Adachi N et al (2025) PHEX protein in the parathyroid gland contributes to phosphate sensing. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf357","journal-title":"J Clin Endocrinol Metab"},{"key":"1468_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1210\/jcem.78.6.8200940","volume":"78","author":"TO Carpenter","year":"1994","unstructured":"Carpenter TO, Mitnick MA, Ellison A et al (1994) Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378\u20131383. https:\/\/doi.org\/10.1210\/jcem.78.6.8200940","journal-title":"J Clin Endocrinol Metab"},{"key":"1468_CR11","unstructured":"U.S. Food and Drug Administration (2018) BLA 761068 Approval Letter: CRYSVITA (burosumab-twza). Silver Spring, MD, USA"},{"key":"1468_CR12","unstructured":"European Medicines A (2017) New medicine for rare bone disease. Crysvita, a medicine for the treatment of X-linked hypophosphataemia, recommended for conditional approval"},{"key":"1468_CR13","unstructured":"Summary Basis of Decision for Crysvita. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00429. Accessed 22 Nov 2025"},{"key":"1468_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency (2019) Report on the Deliberation Results: Crysvita Subcutaneous Injection 10 mg, 20 mg, 30 mg (Burosumab) \u2013 Review Report. Tokyo, Japan"},{"key":"1468_CR15","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (2020) Crysvita (burosumabe): nova indica\u00e7\u00e3o. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA), Bras\u00edlia, Brazil"},{"key":"1468_CR16","unstructured":"Ministry of Food and Drug Safety (2021) 2020 Drug Approval Report. Ministry of Food and Drug Safety (or Republic of Korea), Cheongju, Chungcheongbuk-do, Republic of Korea"},{"key":"1468_CR17","unstructured":"Administration (TGA) TG (2022) Crysvita | Therapeutic Goods Administration (TGA). https:\/\/www.tga.gov.au\/resources\/auspmd\/crysvita. Accessed 22 Nov 2025"},{"key":"1468_CR18","unstructured":"Swissmedic (2020) Summary of the Risk Management Plan (RMP) for Crysvita\u00ae (burosumab) \u2013 Version 1.0 (19 July 2018). Kyowa Kirin S\u00e0rl"},{"key":"1468_CR19","doi-asserted-by":"publisher","first-page":"117324","DOI":"10.1016\/j.bone.2024.117324","volume":"190","author":"R Padidela","year":"2025","unstructured":"Padidela R, Rayner L, Boot AM (2025) Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during Burosumab treatment. Bone 190:117324. https:\/\/doi.org\/10.1016\/j.bone.2024.117324","journal-title":"Bone"},{"key":"1468_CR20","first-page":"33","volume":"97","author":"VV Zhukouskaya","year":"2023","unstructured":"Zhukouskaya VV, Ertl D-A, Berkenou J et al (2023) Hyperparathyroidism after three years of burosumab in children affected with X-linked hypophosphatemia. ESPE Abstr 97:33","journal-title":"ESPE Abstr"},{"key":"1468_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1468_CR22","unstructured":"Veritas Health Innovation Covidence systematic review software. Melbourne, Australia"},{"key":"1468_CR23","unstructured":"National Heart, Lung, and Blood Institute (2013) Study Quality Assessment Tools. U.S. Department of Health and Human Services, Bethesda, MD, USA"},{"key":"1468_CR24","first-page":"460","volume":"94","author":"D Basu","year":"2004","unstructured":"Basu D, Pettifor JM, Kromberg J (2004) X-linked hypophosphataemia in South Africa. South Afr Med J Suid-Afr Tydskr Vir Geneeskd 94:460\u2013464","journal-title":"South Afr Med J Suid-Afr Tydskr Vir Geneeskd"},{"key":"1468_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1507\/endocrj.EJ21-0386","volume":"69","author":"N Ito","year":"2022","unstructured":"Ito N, Kang HG, Nishida Y et al (2022) Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey. Endocr J 69:373\u2013383. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0386","journal-title":"Endocr J"},{"key":"1468_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00223-023-01172-2","volume":"114","author":"A Bosman","year":"2024","unstructured":"Bosman A, Appelman-Dijkstra NM, Boot AM et al (2024) Disease manifestations and complications in Dutch X-Linked Hypophosphatemia Patients. Calcif Tissue Int 114:255\u2013266. https:\/\/doi.org\/10.1007\/s00223-023-01172-2","journal-title":"Calcif Tissue Int"},{"key":"1468_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13052-019-0654-6","volume":"45","author":"F Emma","year":"2019","unstructured":"Emma F, Cappa M, Antoniazzi F et al (2019) X-linked hypophosphatemic rickets: an Italian experts\u2019 opinion survey. Ital J Pediatr 45:67. https:\/\/doi.org\/10.1186\/s13052-019-0654-6","journal-title":"Ital J Pediatr"},{"key":"1468_CR28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40620-024-01962-3","volume":"37","author":"LC L\u00f3pez-Romero","year":"2024","unstructured":"L\u00f3pez-Romero LC, Broseta JJ, Mu\u00f1oz-Casta\u00f1eda JR, Hern\u00e1ndez-Jaras J (2024) X-Linked hypophosphatemia. Data from a Spanish adult population cohort. J Nephrol 37:1251\u20131260. https:\/\/doi.org\/10.1007\/s40620-024-01962-3","journal-title":"J Nephrol"},{"key":"1468_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/eje-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125\u2013136. https:\/\/doi.org\/10.1530\/eje-15-0515","journal-title":"Eur J Endocrinol"},{"key":"1468_CR30","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jc.2009-1671","volume":"95","author":"EA Imel","year":"2010","unstructured":"Imel EA, DiMeglio LA, Hui SL et al (2010) Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95:1846\u20131850. https:\/\/doi.org\/10.1210\/jc.2009-1671","journal-title":"J Clin Endocrinol Metab"},{"key":"1468_CR31","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter TO, Insogna KL, Zhang JH et al (2010) Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95:E352\u2013E357. https:\/\/doi.org\/10.1210\/jc.2010-0589","journal-title":"J Clin Endocrinol Metab"},{"key":"1468_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1210\/js.2018-00338","volume":"3","author":"GP Colares Neto","year":"2019","unstructured":"Colares Neto GP, Ide Yamauchi F, Hueb Baroni R et al (2019) Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors. J Endocr Soc 3:1053\u20131061. https:\/\/doi.org\/10.1210\/js.2018-00338","journal-title":"J Endocr Soc"},{"key":"1468_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","volume":"35","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Chaumet-Riffaud P, Blanchard A et al (2020) Hyperparathyroidism in patients with X-linked hypophosphatemia. J Bone Miner Res 35:1263\u20131273. https:\/\/doi.org\/10.1002\/jbmr.3992","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01468-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:33:31Z","timestamp":1766547211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01468-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01468-5","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs. Freedberg, Neugut, and Samuel A. Fisch receive research funding from Kyowa Kirin and Otsuka; Drs. Tudor, Benchekroun, and Landsberg are employees of Kyowa Kirin International plc. Marlow, UK; Dr. Neugut has consulted for Otsuka, Organon, United Biosource Corp, Merck, Cybin, and Value Analytics. Drs. Neugut and Freedberg receive research support from Otsuka and Kyowa Kirin. The other authors have no conflicts of interest to disclose. Dr. Stein receives research funding from Novartis and Radius Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"4"}}